World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
92
Citations
36890
World Ranking
11173
National Ranking
5748

Overview

Jason Gotlib is affiliated with Stanford University in the United States and has contributed extensively to the fields of Medicine, Immunology, and Microbiology. They have published over 400 academic works, with significant focus on Genetics, Immunology, Rheumatology, Hematology, and Physiology as subfields.

Gotlib's research primarily concentrates on several key topics within medical science, including:

  • Mast cells and histamine
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Urticaria and Related Conditions
  • Asthma and respiratory diseases

The scientist has authored papers in a range of high-impact journals, with frequent publications in:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Journal of Allergy and Clinical Immunology
  • The Journal of Allergy and Clinical Immunology In Practice
  • Blood Advances

Recent notable publications include:

  • International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data (2022, Blood)
  • Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal (2021, HemaSphere)
  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology (2020, Journal of the National Comprehensive Cancer Network)
  • Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts (2020, Theranostics)
  • World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management (2021, American Journal of Hematology)

Collaborations are a significant aspect of Gotlib's work, with frequent co-authors including:

  • Tracy I. George
  • Deepti Radia
  • Daniel J. DeAngelo
  • Karin Hartmann
  • Andreas Reiter

Best Publications

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome

    Jan Cools;Jan Cools;Daniel J. DeAngelo;Jason Gotlib;Elizabeth H. Stover

  • Granulocyte-Macrophage Progenitors as Candidate Leukemic Stem Cells in Blast-Crisis CML

    Catriona H M Jamieson;Laurie E Ailles;Scott J Dylla;Manja Muijtjens

  • Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

    Peter Valent;Amy D. Klion;Hans-Peter Horny;Florence Roufosse

  • Oncogenic CSF3R Mutations in Chronic Neutrophilic Leukemia and Atypical CML

    Julia E. Maxson;Jason Gotlib;Daniel A. Pollyea;Angela G. Fleischman

  • Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis

    Mignon L. Loh;Shashaank Vattikuti;Suzanne Schubbert;Melissa G. Reynolds

  • Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis

    Jason Gotlib;Hanneke C. Kluin-Nelemans;Tracy I. George;Cem Akin

  • Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis

    Animesh Pardanani;Jason R. Gotlib;Catriona Jamieson;Jorge E. Cortes

  • Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

    G. Barosi;R. A. Mesa;J. Thiele;F. Cervantes

  • Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report

    Ayalew Tefferi;Francisco Cervantes;Ruben Mesa;Francesco Passamonti

  • Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).

    Ruben A. Mesa;Srdan Verstovsek;Francisco Cervantes;Giovanni Barosi

  • Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms

    Stephen T. Oh;Erin F. Simonds;Carol Jones;Matthew B. Hale

  • Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology

    Karin Hartmann;Luis Escribano;Clive Grattan;Knut Brockow

  • Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

    Srdan Verstovsek;Ruben A Mesa;Jason R Gotlib;Vikas Gupta

  • The FIP1L1-PDGFRα fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management

    Jason Gotlib;Jason Gotlib;Jason Gotlib;Jan Cools;Jan Cools;Jan Cools;James M. Malone;James M. Malone;James M. Malone;Stanley L. Schrier;Stanley L. Schrier;Stanley L. Schrier

  • The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation

    Catriona H. M. Jamieson;Jason Gotlib;Jeffrey A. Durocher;Mark P. Chao

  • Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

    Jason Gotlib;Caroline Berubé;Joseph D. Growney;Ching Cheng Chen

  • A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

    F Passamonti;T Giorgino;B Mora;P Guglielmelli

  • Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial

    John Mascarenhas;Ronald Hoffman;Moshe Talpaz;Aaron T. Gerds

  • NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia.

    O'Brien S;Berman E;Borghaei H;Deangelo Dj

Frequent Co-Authors

Ruben A. Mesa
Ruben A. Mesa The University of Texas Health Science Center at San Antonio
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Peter Valent
Peter Valent Medical University of Vienna
Michael W. Deininger
Michael W. Deininger University of Utah
Andreas Reiter
Andreas Reiter Heidelberg University
Karin Hartmann
Karin Hartmann University Hospital of Basel
Vikas Gupta
Vikas Gupta Princess Margaret Cancer Centre
Cem Akin
Cem Akin University of Michigan–Ann Arbor
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Richard T. Silver
Richard T. Silver Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medicine but seeking flexible learning options, there are a variety of online health degree pathways to consider. A popular choice is pursuing a nursing degree online, which can open doors to a rewarding career in patient care. These programs allow students to balance work and study, making them ideal for busy professionals or career changers.

For registered nurses aiming to advance, the cheapest accredited online rn to bsn programs offer an accessible route to earning a bachelor’s degree. Additionally, those aspiring to leadership, research, or teaching roles in nursing can benefit from online phd programs in nursing, providing advanced knowledge and skills at the doctoral level.

If you hold a non-nursing bachelor’s degree and want to enter the nursing field quickly, msn direct entry programs online may be the right fit. These accelerated programs prepare students for licensure and graduate-level nursing roles, expanding career opportunities within the healthcare sector.

Best Scientists Citing Jason Gotlib

Trending Scientists

Recently Published Articles